XORTX Therapeutics (XRTX) Liabilities and Shareholders Equity (2020 - 2026)

XORTX Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 38.7% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.4 million (down 36.09% YoY) and the FY2025 annual result came in at $2.7 million, down 34.46% from the prior year.
• Liabilities and Shareholders Equity was $2.1 million for Q1 2026 at XORTX Therapeutics, down from $2.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $14.6 million in Q1 2022 and bottomed at $2.1 million in Q1 2026.
• A 5-year average of $6.7 million and a median of $5.4 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 84.35% — and 2025, when it slumped 42.87%.
• XORTX Therapeutics' Liabilities and Shareholders Equity stood at $12.3 million in 2022, then slumped by 46.2% to $6.6 million in 2023, then sank by 38.34% to $4.1 million in 2024, then plunged by 34.46% to $2.7 million in 2025, then declined by 20.08% to $2.1 million in 2026.
• Business Quant data shows XRTX's Liabilities and Shareholders Equity at $2.1 million in Q1 2026, $2.7 million in Q4 2025, and $2.8 million in Q3 2025.